The Netherlands
Sensius, headquartered in The Netherlands, operates at the intersection of Biotechnology, Health Care, and Medical Devices. Founded in 2015, the company is pioneering the integration of thermotherapy in cancer treatment, aiming to position it alongside established modalities such as radiotherapy and chemotherapy.
Sensius’s mission centers on enhancing radiotherapy outcomes for head and neck cancer patients by balancing treatment efficacy with maintaining quality of life. Their innovative approach highlights a potential shift in oncological treatment paradigms.
In the financial realm, Sensius recently secured a €1.70M grant investment from the European Innovation Council in February 2023, signifying strong institutional confidence in their technology and growth prospects. This funding is crucial for scaling operations and further developing their therapeutic offerings.
